TP53 R249S mutation in hepatic organoids captures the predisposing cancer risk
Yin Kau Lam, Jianqing Yu, Hao Huang, Xiaofan Ding, Alissa M. Wong, Howard H. Leung, Anthony W. Chan, Kelvin K. Ng, Mingjing Xu, Xin Wang, Nathalie Wong – 10 October 2022
Validation of novel point‐of‐care test for alanine aminotransferase measurement: A pilot cohort study
Jessica Howell, Huy Van, Minh Pham, Rohit Sawhney, Fan Li, Purnima Bhat, John Lubel, William Kemp, Stephen Bloom, Avik Majumdar, Geoff McCaughan, Samuel Hall, Timothy Spelman, Joseph S. Doyle, Margaret Hellard, Kumar Visvanathan, Alexander J. Thompson, Heidi E. Drummer, David Anderson – 9 October 2022
Posttransplant considerations in autoimmune liver disease: Recurrence of disease and de novo
Alexis Gumm, Antonio Perez‐Atayde, Andrew Wehrman – 9 October 2022
Validation of novel point‐of‐care test for alanine aminotransferase measurement: A pilot cohort study
Jessica Howell, Huy Van, Minh Pham, Rohit Sawhney, Fan Li, Purnima Bhat, John Lubel, William Kemp, Stephen Bloom, Avik Majumdar, Geoff McCaughan, Samuel Hall, Timothy Spelman, Joseph S. Doyle, Margaret Hellard, Kumar Visvanathan, Alexander J. Thompson, Heidi E. Drummer, David Anderson – 9 October 2022
Posttransplant considerations in autoimmune liver disease: Recurrence of disease and de novo
Alexis Gumm, Antonio Perez‐Atayde, Andrew Wehrman – 9 October 2022
Psychosocial considerations in pediatric autoimmune liver disease
Brianna C. M. Wellen, Henry C. Lin, Jacklyn E. Stellway – 9 October 2022
Psychosocial considerations in pediatric autoimmune liver disease
Brianna C. M. Wellen, Henry C. Lin, Jacklyn E. Stellway – 9 October 2022
Psychosocial considerations in pediatric autoimmune liver disease
Brianna C. M. Wellen, Henry C. Lin, Jacklyn E. Stellway – 9 October 2022
Reply
Manuel Mendizabal, Nicolás Ducasa, Paula Benencio, Mirna Biglione, Ezequiel Mauro – 9 October 2022
Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid
Dawei Ding, Guanya Guo, Yansheng Liu, Linhua Zheng, Gui Jia, Juan Deng, Ruiqing Sun, Xiufang Wang, Changcun Guo, Yulong Shang, Ying Han – 9 October 2022 – Fenofibrate (FF) has shown potential benefits in patients with primary biliary cholangitis (PBC) who have an incomplete response to ursodeoxycholic acid (UDCA). However, the efficacy and safety of FF in patients with cirrhosis remain unclear.